Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …

SGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD).
But the mechanism for such protection is not clear. Here, we report that in damaged proximal …

Chronic kidney disease (CKD) causes substantial global morbidity and increases
cardiovascular and all-cause mortality. Unlike other chronic diseases with established …

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …

Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem,
resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the …

Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …

Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …